Comparative evaluation of safety parameters at the preclinical and clinical stages of the study of the Reamberin® (LLC "POLYSAN")

Relevance. Interpretation of the preclinical trials data is fundamental importance. The correctness of extrapolation of data obtained from animals to humans is due to the qualitative and quantitative diversity of the systems tested the recorded parameters and approaches to their interpretation, as well as statistical methods in determining the possible risk to humans.

Aim. Comparative assessment of the safety and tolerability parameters obtained during the preclinical and clinical trials of the Reamberin® (LLC «POLYSAN») and the development of approaches to improving clinical trial planning processes for assessing safety and tolerability, taking into accounts the results of preclinical studies.

Materials and methods. A comparative analysis of the safety parameters that arose during a clinical study involving healthy volunteers and deviations from the control levels of clinical and laboratory parameters established at the stage of a preclinical study on outbred rats and rabbits of the chinchilla breed of a drug with an international non-proprietary name (INN): meglumine sodium succinate (trade name (TN) Reamberin® (LLC «POLYSAN»)).

Results. Unidirectional deviations from normal (control) values were established. Isolated cases of adverse events among healthy volunteers (increased activity of hepatic transaminases, changes in blood pressure) were identified. This facts didn't correlate with the preclinical study. The number of comparable indicators in laboratory animals, for which statistically significant differences were established between the experimental and control groups, significantly exceeded the number of signs in the form of adverse events among healthy volunteers.

1. Narkevich IA, Nemyatykh OD, Basakina II, Siukaeva DD. Pharmaceutical development of drugs for pediatric practice: fundamental bases and specific features. Drug development & registration. 2016;3(16): 194-201. (In Russ).].

2. GOST R 56699-2015 of 1st July 2016. «Lekarstvennye sredstva dlya medicinskogo primeneniya. Doklinicheskie issledovaniya bezopasnosti biotekhnologicheskih lekarstvennyh preparatov. Obshchie rekomendacii». (In Russ).]. URL: https://files.stroyinf.ru/Data2/1/4293758/4293758351.pdf. Ссылка активна на 11.07.2022.

3. Ich.org [Internet]. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Available from: [cited 2022 Jul 11] https://www.ich.org/

4. World medical association declaration of Helsinki (In Russ).]. URL: https:// www.asmu.ru/upload/iblock/067.pdf Ссылка активна на 11.07.2022.

5. Reshenie Kollegii Evrazijskoj ekonomicheskoj komissii of 26 November 2019 № 202 "Ob utverzhdenii Rukovodstva po doklinicheskim issledovaniyam bezopasnosti v celyah provedeniya klinicheskih issledovanij i registracii lekarstvennyh preparatov"]. URL: https://www.alta.ru/tamdoc/19kr0202. Ссылка актив¬на на 11.07.2022.

6. GOST R 56701-2015. Nacional'nyj standart Rossijskoj Federacii. Lekarstvennye sredstva dlya medicinskogo primeneniya. Rukovodstvo po planirovaniyu doklinicheskih issledovanij bezopasnosti s cel'yu posleduyushchego provedeniya klinicheskih issledovanij i registracii lekarstvennyh sredstv" (In Russ).]. URL: https:// www.alta.ru/tamdoc/19kr0202. Ссылка активна на 11.07.2022

7. Ema.europa.eu [Internet]. Concept paper on the Need for Revision of the note for Guidance on Photosafety testing (CPMP/SWP/398/01), EMEA/CHMP/ SWP/ 534549/2007; January 2008 [cited 2022 Jul 11]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-photosafety-testing_en.pdf

8. Ema.europa.eu [Internet]. Concept paper on the Need for Revision of the Guideline on non-clinical local tolerance testing of medicinal products (CPMP/SWP/2145/00), EMA/CHMP/ SWP/708666/2010; July 2011 [cited 2022 Jul 11]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-non-clinical-local-tolerance-testing-medicinal-products_en.pdf

9. Ema.europa.eu [Internet]. ICH S2(R1) Guidance on Genotoxicity testing and data interpretation for pharmaceuticals intended for human use; November 2011 2011 [cited 2022 Jul 11]. Available from: https://www.ema. europa.eu/en/ich-s2-r1-genotoxicity-testing-data-interpretation-pharmaceuticals-intended-human-use

10. Guidance for Industry. Assessment of Abuse Potential of Drugs. Food and Drug Administration Center for Drug Evaluation and Research (CDER); January 2010

11. Ema.europa.eu [Internet]. Overview of comments received on draft guideline on the need for non-clinical testing in juvenile animals of human pharmaceuticals for paediatric indications Doc. ref. EMEA/425007/2007; May 2009 [cited 2022 Jul 11]. Available from:https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-need-non-clinical-testing-juvenile-animals-human_en.pdf

12. Ema.europa.eu [Internet]. The International Conference on Harmonisation. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3(R2)). 2009 [cited 2022 Jul 11]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-marketing-authorisation_en.pdf

13. Ema.europa.eu [Internet]. The International Conference on Harmonisation. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (ICH S6(R1)). 2011 [cited 2022 Jul 11]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s6r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals-step-5_en.pdf

14. Volskaya E. Reformation of clinical trials management in the EU. Remedium. 2015:6-14 (In Russ).].

15. Syraeva GI, Kolbin AS, Matveev AV, Panezhina VS. Comparative review of methodologies for estimating the cost of adverse drug reactions in the Russian Federation and Brazil. Pharmacy & Pharmacology. 2020;8(5):336-344. (In Russ).]. DOI: 10.19163/2307¬9266-2020-8-5-336-344

16. Resolution of the Chief State Sanitary Doctor of the Russian Federation dated 29.08.2014 No. 51 on approval of SP 2.2.1.3218-14 «Sanitarno-epidemiologicheskie trebovaniya k ustrojstvu, oborudovaniyu i soderzhaniyu eksperimental'no-biologicheskih klinik (vivariev). (In Russ).]. URL: https://34.rospotrebnadzor.ru/content/282/6555. Ссылка активна на 11.07.2022.

17. European Convention for the Protection of Vertebrate Animals. (In Russ).]. URL: https://www.academpharm.ru/images/upload/ru/1241/evropeskaya_konvenciya_ETS123.pdf Ссылка активна на 11.07.2022.

18. GOST R 53434-2009 National standard of the Russian Federation «Principy nadlezhashchej laboratornoj praktiki» (In Russ).]. URL: https://meganorm.ru/Data/486/48600.pdf Ссылка активна на 11.07.2022.

19. Order of the Ministry of Health and Social Development of the Russian Federation No. 708n dated August 23, 2010 «Ob utverzhdenii pravil laboratornoj praktiki» (In Russ).]. URL: https://www.garant.ru/products/ipo/prime/doc/12079613. Ссылка активна на 11.07.2022.

20. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv / Ed by AN Mironova. Chast' pervaya. Moscow: Grif i K; 2012. (In Russ).].

21. Otchet o rezul'tatah klinicheskogo issledovaniya po teme: «Otkrytoe, randomizirovannoe issledovanie bezopasnosti, perenosimosti preparata Reamberin®, 1,5%, rastvor dlya infuzij (OOO «NTFF «POLISAN») pri odnokratnom vnutrivennom infuzionnom vvedenii preparata v razlichnyh dozirovkah i s razlichnoj skorost'yu zdorovym dobrovol'cam, i farmakokinetiki preparata Reamberin®, 1,5%, rastvor dlya infuzij (OOO «NTFF «POLISAN») pri odnokratnom vnutrivennom infuzionnom vvedenii preparata ob'emom 2000 ml so skorost'yu 10 ml/min u zdorovyh dobrovol'cev», Saint-Petersburg, 2019. (In Russ).].

22. Yengalycheva GN, Syubaev RD, Merkulov VA, Vasilyev AN. Evaluating the results of drug preclinical safety studies. Vedomosti Nauchnogo centra ekspertizy sredstv medicinskogo primeneniya. 2013;(2):9—11. (In Russ).].

23. Ema.europa.eu [Internet]. Concept paper on the Need for Revision of the Position on the Replacement of Animal Studies by in vitro Models (CPMP/SWP/728/95), EMA/CHMP/ SWP/169839/2011; March 2011 [cited 2022 Jul 11]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/revised-concept-paper-need-revision-position-replacement-animal-studies-vitro-models_en.pdf

24. Trahtenberg IM, Sova RE, SHeftel' VO, Onikienko FA. Problema normy v toksikologii (sovremennye predstavleniya i metodicheskie podhody, osnovnye parametry i konstanty) / Ed by IM Trahtenberg. Moscow: Medicina; 1991. (In Russ).].

25. Abrashova TV, Gushchin YaA, Kovaleva MA, Rybakova AV, Selezneva AI, Sokolova AP, Hod'ko SV. Spravochnik. Fiziologicheskie, biohimicheskie i biometricheskie pokazateli normy eksperimental'nyh zhivotnyh / Ed by Makarova VG, Makarovoj MN. Saint-Petersburg; 2013. (In Russ).].